References
- Ruan J, Hajjar K, Rafii S, et al. Angiogenesis and antiangiogenesis therapy in non-Hodgkin's lymphoma. Ann Oncol 2009;20:413–424.
- Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.
- Riihijärvi S, Nurmi H, Holte H, et al. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. Eur J Haematol 2012;89:395–402.
- Paydas S, Seydaoglu G, Ergin M, et al. The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:366–373.
- Gratzinger D, Advani R, Zhao S, et al. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol 2009;148:235–244.
- Seymour JF, Pfreundshuh M, Coiffier B, et al. The addition of bevacizumab to standard therapy with R-CHOP in patients with previously untreated diffuse large B-cell lymphoma is associated with an increased rate of cardiac adverse events: final analysis of safety and efficacy outcomes from the placebo-controlled phase 3 MAIN study. Blood 2012;120(Suppl. 1): Abstract 58.
- Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997;16: 3898–3911.
- Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007;8:464–478.
- Pazgal I, Boycov O, Shpilberg O, et al. Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymphoma 2007;48:2213–2220.
- Ganjoo KN, Moore AM, Orazi A, et al. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol 2008;134:381–387.
- Rueda A, Sabin P, Rifá J, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematol Oncol 2008;26:27–32.
- Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90: 3167–3172.
- Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012;26:2103–2113.
- Friedberg JW. Double-hit diffuse large B-cell lymphoma. J Clin Oncol 2012;30:3439–3443.
- Jaffe ES, Harris NL, Stein H, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.